Goldman Urology Clinic has recently achieved a milestone of 6,000 cumulative surgeries for benign prostatic hyperplasia (BPH), demonstrating its clinical capability in the treatment of prostate enlargement. The milestone reflects the clinic’s approach of applying personalized treatment strategies based on a broad range of surgical options tailored to each patient’s condition.
Benign prostatic hyperplasia is a common condition among middle-aged and older men. As the prostate enlarges, it compresses the urethra and causes lower urinary tract symptoms such as frequent urination, nocturia, a sensation of incomplete bladder emptying, and delayed urination. In the early stages, symptoms can often be managed with medication. However, when medication becomes less effective or symptoms persist or worsen, surgical treatment may be required. At that stage, physicians must consider multiple factors—including prostate size and shape, symptom severity, presence of complications, underlying chronic diseases, anesthesia conditions, and recovery planning—in order to select the most appropriate treatment method for each patient.
Based on these principles, Goldman Urology Clinic has continuously introduced advanced surgical techniques and refined its clinical protocols. These include Rezūm therapy, which injects high-temperature steam to induce necrosis and shrink enlarged prostate tissue; Aquablation (robotic waterjet surgery), which uses high-pressure water guided by an AI-based robotic system to precisely remove prostate tissue without thermal damage; and Holmium Laser Enucleation of the Prostate (HoLEP), a procedure that removes enlarged prostate tissue using a holmium laser.
In addition, the clinic offers other treatment options such as the iTind device, which temporarily expands the prostatic urethra, and the UroLift system, which reduces the burden of surgical tissue removal. By offering multiple treatment approaches, the clinic has established a personalized treatment strategy that takes into account prostate size, anatomical structure, and symptom severity.
Goldman Urology Clinic has also continued research on benign prostatic hyperplasia based on more than two million accumulated clinical cases over the past 20 years. These research efforts have contributed to clinical outcomes in real-world practice and have been positively recognized. For example, the clinic has presented research findings related to robotic waterjet surgery at academic conferences and has continuously evaluated and refined the safety and effectiveness of new surgical techniques in actual clinical settings.
Dr. Lee Chang-gi, CEO and lead physician of Goldman Urology Clinic, explained that outcomes in BPH surgery depend on factors such as the surgeon’s experience, the accuracy of preoperative evaluation, and the quality of postoperative care. He noted that physicians across all branches of Goldman Urology Clinic regularly share clinical data and collaborate to improve treatment protocols, enhancing both consistency and safety in patient care.
He also emphasized that benign prostatic hyperplasia affects each patient differently. Because symptoms, underlying conditions, and recovery plans vary from person to person, it is not appropriate to consider a single surgical method as the universal solution. Instead, he explained, the key principle is to recommend the most suitable treatment option at the appropriate time based on the individual needs and condition of each patient.